Electrochemiluminescence lateral flow immunosensor using luminol-labeled silver nanoparticles for highly sensitive
Jun Chen1, Xuanxu Nan1, Li Yang2
1School of Materials Science and Engineering, Peking University, Beijing, 100871, PR China.
Insights
A new electrochemiluminescence lateral flow immunosensor (ECL-LFI) detects cardiac troponin I (cTnI) at very low levels. This sensitive sensor offers a promising tool for the early diagnosis of acute myocardial infarction (AMI).
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Cardiovascular Diagnostics
Background:
- Cardiac troponin I (cTnI) is a critical biomarker for diagnosing acute myocardial infarction (AMI).
- Early detection of AMI requires highly sensitive sensors due to the very low concentrations of cTnI released.
- Existing diagnostic methods may lack the necessary sensitivity or speed for rapid point-of-care testing.
Purpose of the Study:
- To develop a sensitive and quantitative electrochemiluminescence lateral flow immunosensor (ECL-LFI) for cardiac troponin I (cTnI) detection.
- To evaluate the performance of the ECL-LFI for early diagnosis of acute myocardial infarction (AMI).
Main Methods:
- Designed an ECL-LFI using luminol-labeled silver nanoparticles (luminol@AgNPs).
- Integrated a screen-printed electrode (SPE) with a nitrocellulose (NC) membrane for sample flow.
- Utilized sandwich immunoassay principles to generate electrochemiluminescent (ECL) signals upon cTnI detection.
Main Results:
- The ECL-LFI demonstrated a broad linear detection range from 5 pg/mL to 100 ng/mL.
- Achieved a highly sensitive detection limit as low as 1.6 pg/mL for cTnI.
- Exhibited excellent correlation with clinical diagnostic tests.
Conclusions:
- The developed ECL-LFI is a highly sensitive and quantitative tool for cTnI detection.
- This sensor shows significant promise as a point-of-care diagnostic tool for early AMI detection.
- The technology can potentially be applied to diagnose other diseases requiring biomarker detection.
Abstract:
Cardiac troponin I (cTnI) is a highly specific biomarker of cardiomyocyte injury, released during cell disintegration and necrosis, and is the gold standard for diagnosing acute myocardial infarction (AMI). At the onset of AMI, cTnI appears in very low concentrations (pg/mL level), necessitating the development of highly sensitive and rapid detection sensors. In this study, an electrochemiluminescence lateral flow immunosensor (ECL-LFI) was designed using luminol-labeled silver nanoparticles (luminol@AgNPs) for the sensitive and quantitative detection of cTnI. A screen-printed electrode (SPE) was integrated beneath the nitrocellulose (NC) membrane with plastic plates of the same thickness applied on both sides of the SPE to ensure a smooth flow surface. Upon addition of cTnI and the luminol-H2O2 system, sandwich immune complexes formed by antibody-functionalized luminol@AgNPs on the strips generated electrochemiluminescent (ECL) signals. The ECL-LFI exhibited a broad linear detection range from 5 pg/mL to 100 ng/mL, with a detection limit as low as 1.6 pg/mL. Additionally, the results show excellent correlation with clinical tests, demonstrating that the ECL-LFI provides a promising point-of-care tool for the early diagnosis of AMI and other diseases.
More Related Videos
Related Concept Videos
01:33Enzyme-Linked Immunosorbent Assay
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...